Evidence map›Paper›PMID 32390485›Full record

ArticleJournal of the American Heart Association2020

Nonlethal Inhibition of Gut Microbial Trimethylamine N-oxide Production Improves Cardiac Function and Remodeling in a Murine Model of Heart Failure.

Chelsea L Organ, Zhen Li, Thomas E Sharp, David J Polhemus, Nilaksh Gupta, Traci T Goodchild, W H Wilson Tang, Stanley L Hazen, David J Lefer

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 117 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Raman signatures ofFrontiers in microbiology · 2026
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Chelsea L OrganCardiovascular Center of Excellence Louisiana State University Health Sciences Center New Orleans LA.
Zhen LiCardiovascular Center of Excellence Louisiana State University Health Sciences Center New Orleans LA.
Thomas E SharpCardiovascular Center of Excellence Louisiana State University Health Sciences Center New Orleans LA.
David J PolhemusCardiovascular Center of Excellence Louisiana State University Health Sciences Center New Orleans LA.
Nilaksh GuptaCenter for Microbiome and Human Health Department of Cardiovascular and Metabolic Sciences Lerner Research Institute Cleveland Clinic Cleveland OH.
Traci T GoodchildCardiovascular Center of Excellence Louisiana State University Health Sciences Center New Orleans LA.
W H Wilson TangCenter for Microbiome and Human Health Department of Cardiovascular and Metabolic Sciences Lerner Research Institute Cleveland Clinic Cleveland OH.
Stanley L HazenCenter for Microbiome and Human Health Department of Cardiovascular and Metabolic Sciences Lerner Research Institute Cleveland Clinic Cleveland OH.
David J LeferCardiovascular Center of Excellence Louisiana State University Health Sciences Center New Orleans LA.
Louisiana State University Health Sciences Center New Orleans · USCleveland Clinic Lerner College of Medicine · USCleveland Clinic · US

Funding

Project 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic diseaseP01HL147823 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MICHAEL ANDREW FISCHBACH · 2019 to 2026
$17.0M
Gut Flora Metabolism of Dietary Phosphatidylcholine and CVDR01HL103866 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HAZEN, STANLEY L · 2010 to 2023
$10.8M
Preclinical Consortium to Facilitate Translation of Cardioprotective TherapiesU24HL094373 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2010 to 2014
$9.6M
Diet, Gut Microbiota, and Heart FailureR01HL126827 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HAZEN, STANLEY L, TANG, WAI HONG WILSON · 2016 to 2019
$3.1M
Cardioprotective Actions of Hydrogen SulfideR01HL092141 · NHLBI · LSU HEALTH SCIENCES CENTER · PI LEFER, DAVID JOSEPH · 2009 to 2013
$1.9M
Endogenous Hydrogen Sulfide Enzymes in Heart FailureR01HL146098 · NHLBI · LSU HEALTH SCIENCES CENTER · PI XIA, HUIJING · 2019 to 2022
$1.6M
Nitrite Mediated CardioprotectionR01HL093579 · NHLBI · LSU HEALTH SCIENCES CENTER · PI LEFER, DAVID JOSEPH · 2009 to 2012
$1.5M
AB/SCIEX QTrap 6500 Mass Spectrometer Metabolic profiling systemS10OD016346 · OD · CLEVELAND CLINIC LERNER COM-CWRU · PI DIDONATO, JOSEPH · 2014 to 2014
$600k
NHLBI NIH HHS P01 HL147823NHLBI NIH HHS R01 HL092141NHLBI NIH HHS R01 HL093579NHLBI NIH HHS R01 HL103866NHLBI NIH HHS R01 HL126827NHLBI NIH HHS R01 HL146098NHLBI NIH HHS U24 HL094373
6 · The paper itself

Abstract

Background Patients at increased risk for coronary artery disease and adverse prognosis during heart failure exhibit increased levels of circulating trimethylamine N-oxide (TMAO), a metabolite formed in the metabolism of dietary phosphatidylcholine. We investigated the efficacy of dietary withdrawal of TMAO as well as use of a gut microbe-targeted inhibitor of TMAO production, on cardiac function and structure during heart failure. Methods and Results Male C57BLK/6J mice were fed either control diet, a diet containing TMAO (0.12% wt/wt), a diet containing choline (1% wt/wt), or a diet containing choline (1% wt/wt) plus a microbial choline trimethylamine lyase inhibitor, iodomethylcholine (0.06% wt/wt), starting 3 weeks before transverse aortic constriction. At 6 weeks after transverse aortic constriction, a subset of animals in the TMAO group were switched to a control diet for the remainder of the study. Left ventricular structure and function were monitored at 3-week intervals. Withdrawal of TMAO from the diet attenuated adverse ventricular remodeling and improved cardiac function compared with the TMAO group. Similarly, inhibiting gut microbial conversion of choline to TMAO with a choline trimethylamine lyase inhibitor, iodomethylcholine, improved remodeling and cardiac function compared with the choline-fed group. Conclusions These experimental findings are clinically relevant, and they demonstrate that TMAO levels are modifiable following long-term exposure periods with either dietary withdrawal of TMAO or gut microbial blockade of TMAO generation. Furthermore, these therapeutic strategies to reduce circulating TMAO levels mitigate the negative effects of dietary choline and TMAO in heart failure.

Indexed as

AnimalsBacteriaBacterial ProteinsCholineDisease Models, AnimalDown-RegulationEnzyme InhibitorsFibrosisGastrointestinal MicrobiomeHeart FailureIntestinesLyasesMaleMethylaminesMice, Inbred C57BLMyocardiumBacterial ProteinsCholineEnzyme InhibitorsLyasesMethylaminestrimethyloxaminecardiac fibrosisdietary cholinegut microbiotametabolomics

Identifiers

PMID32390485
PMCPMC7660847
OpenAlexW3021372222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.